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Colorectal carcinomas (CRCs) with high microsatellite instability (MSI-H) share clinicopathological features distinctly different from
their microsatellite stable (MSS) counterparts. Unlike MSS cancers, MSI-H CRCs occur predominantly in the right-sided colon and are
often characterised by a strong lymphocyte infiltration. A poor differentiation pattern is found in most MSI-H CRCs, even though
patients with MSI-H carcinomas seem to have a significantly longer survival after surgical resection. To clarify which factors contribute
to the obvious paradoxon of a more favourable prognosis of MSI tumours, several clinical and histopathological features as well as the
microsatellite status were evaluated in 120 colorectal cancer cases fulfilling clinical criteria (Bethesda) indicative for familial colorectal
cancer. Microsatellite instablity status and lymphocyte infiltration were related to tumour stage and patients’ follow-up. Statistical
analysis confirmed well-known relations, such as enhanced lymphocyte infiltration accompanied by Crohn’s like reaction (CLR) in
MSI-H cancers (CLRþ in 27 out of 47 MSI-H vs 14 out of 71 MSS CRCs, Po0.001). However, after stratification for depth of local
invasion and penetration of the primary tumour, T3 tumours displaying MSI had a significantly lower rate of distant metastases (M1 in
four out of 35 MSI-H vs 20 out of 41 MSS CRCs, Po0.001). A similar tendency was observed for CLR-positive CRCs (M1 in six out
of 29 CLRþ vs 17 out of 45 CLR  CRCs, P¼0.13). In a logistic regression model, the MSI-H phenotype and the presence of CLR
were independent predictors of a low UICC stage (P¼0.006 and 0.04, respectively). These data, together with the recent definition
of highly immunogenic neo-antigens expressed in MSI-H tumour cells, suggest that MSI-H CRCs elicit a protective host response that
may prevent metastasis formation.
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Colorectal cancer is one of the most common causes of cancer-
related deaths in the Western world. Even though preventive
cancer screening contributes to a decrease of colorectal cancer
incidence in the elderly, recent reports indicate increasing rates in
the younger population (O’Connell et al, 2003). Colorectal cancer
remains a major health problem causing significant morbidity and
mortality, especially in industrialised countries. In Germany, about
57000 novel cases of colorectal cancer are recorded each year
(Becker, 2003).
Colorectal carcinomas (CRCs) generally arise from precancerous
lesions by accumulation of mutations in genes coding for proteins
involved in controlling cell growth and differentiation. For the
development of colorectal cancer, two major pathways have been
described. The more common pathway is characterised by large
genomic rearrangements (Lengauer et al, 1997), which are found
in about 85% of colon cancers. An exemplary multistep model,
which is called the chromosomal instability (CIN) pathway, has
been described by Fearon and Vogelstein (1990). According to this
schematic process, the inactivation of the APC tumour suppressor
gene is a key event in early tumorigenesis, whereas mutations of
the TP53 gene occur at a late stage and thus contribute to the
development of a malignant phenotype and invasive tumour
growth. A second pathway is characteristic for patients with the
autosomal-dominant hereditary non-polyposis colorectal cancer
(HNPCC) syndrome, a condition which is found in 2–5% of all
colorectal cancer patients. Hereditary non-polyposis colorectal
cancer familial cancer syndrome is caused by germline mutations
in genes coding for proteins of the DNA mismatch repair (MMR)
system, hMLH1 and hMSH2 are most frequently affected (Boland
(2000) for a review see Lynch and de la Chapelle, 2003). Defects in
the MMR system lead to the accumulation of mutations at short
repetitive DNA sequences, termed microsatellites. Most of them
are localised in noncoding regions of the genome. However,
certain growth-inhibiting or proapoptotic genes, for example,
TGFbRII, BAX, hMSH3 and hMSH6, harbour microsatellites within
their coding sequence (Markowitz et al, 1995; Malkhosyan et al,
1996; Woerner et al, 2003). Insertion/deletion mutations at these
loci cause translational frameshifts and lead to a loss of function of
the corresponding proteins, thereby contributing to the progres-
sion of neoplastic transformation (Furlan et al, 2002). The
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smicrosatellite instability (MSI) pathway also contributes to about
15% of sporadic CRCs. In most MSI cases without family history of
cancer, promoter methylation of the hMLH1 gene is supposed to
be the underlying mechanism (Kane et al, 1997; Miyakura et al,
2001). Although recent work indicates that there are overlaps of
the CIN and MSI pathways in a considerable number of cases (Goel
et al, 2003), the consideration of MSI and CIN as separate
mechanisms of tumorigenesis seems well justified.
Colorectal carcinoma of the MSI phenotype displays several
clinicopathological features distinctly different from those found
in CIN CRC. High-grade microsatellite unstable (MSI-H) colon
tumours predominantly have a right-sided location and frequently
present with a strong lymphocyte infiltration (Smyrk et al, 2001).
The presence of characteristic lymphocyte aggregations, the so-
called Crohn’s like reaction (CLR, Graham and Appelman, 1990),
has also been reported to be more frequent in MSI-H colon cancer
(Alexander et al, 2001; Greenson et al, 2003). Many MSI-H
carcinomas display a poor differentiation pattern, often with
mucinous or signet cell areas (Greenson et al, 2003). Data on the
prognosis of MSI-H CRC are conflicting. Salahshor et al (1999)
found an obvious trend towards a better outcome of their MSI-H
collective, but this was not statistically significant. Feeley et al
(1999) could not see any impact of microsatellite status on
patients’ survival at all, but the validity of this study is limited by
the low number of MSI-H cases. In summary, however, most
studies revealed a longer disease-free and overall survival for
patients with MSI-H CRC compared to MSS CRC (Watson et al,
1998; Gryfe et al, 2000; Samowitz et al, 2001).
For a better prognostic assessment, Dolcetti et al (2002) suggest
the combination of both the evaluation of local lymphocytosis and
the microsatellite status; MSI in combination with a high content
of intraepithelial cytotoxic lymphocytes was found to be related
with an improved overall survival in a group of exclusively right-
sided CRCs (Guidoboni et al, 2001).
To determine the relative impact of microsatellite status and
antitumoural lymphocyte reaction on the course of disease, we
analysed histological and molecular features of CRCs in patients
clinically suspicious of HNPCC and compared them with tumour
stage and overall survival of the patients.
MATERIALS AND METHODS
Patients’ characteristics
Tumour specimens from 120 patients treated for colorectal cancer
in the Department of Surgery, University Hospital of Heidelberg,
from 1992 to 2002 were included in this prospective study. The
study collective consists of 120 samples consecutively obtained for
microsatellite analysisin the Institute of Molecular Pathology,
University of Heidelberg. Histopathological assessment, micro-
satellite analysis and genetic testing were performed with informed
consent of all patients. Only patients fulfilling Amsterdam or
Bethesda criteria (Table 1, Vasen et al, 1991; Rodriguez-Bigas et al,
1997; Boland et al, 1998), that is, patients suspicious of HNPCC,
were included in this study. From 120 patients included, 21
(17.5%) fulfilled Amsterdam criteria, among the remaining 99
(82.5%), 23 (19.2%) fulfilled Bethesda 2, three (2.5%) Bethesda 3
and 73 (60.8%) Bethesda 4 criteria.Of these, 66 (55.0%) of the
patients were male, 54 (45.0%) were female. In all, 20 patients had
from two (14 patients) to six (one patient) synchronous CRCs.
Patients diagnosed with synchronous tumours in extracolonic
localisation were generally excluded. 5-Fluorouracil (5-FU) che-
motherapy was administered to nine patients with UICC stage II,
18 patients with UICC stage III and 24 patients with UICC stage IV.
Chemotherapeutic regimens were recorded for all patients
included.
Tissue preparation
Surgically resected colonic cancer samples were fixed in formalin
(4–10%) and embedded in paraffin. Tissue sections were prepared
for DNA isolation and subsequent microsatellite marker amplifi-
cation (10mm) as well as for pathohistological analysis (2mm).
Microsatellite analysis
DNA was isolated from microdissected tumour and normal tissue
using the Qiagen DNeasy Tissue Kit (Qiagen, Hilden, Germany).
Microsatellite status was determined using 5–10 markers from the
standard ICG-HNPCC marker panel (Boland et al, 1998). PCR
products were amplified with fluorescein-labelled oligonucleotide
primers as described previously (Sutter et al, 1999). Labelled PCR
products were separated on an ABI3100 analyser (Applied
Biosystems, Darmstadt, Germany), results were analysed using
the GeneScan software version 3.7 (Applied Biosystems) as
previously described (Woerner et al, 2003).
According to the recommendations of the National Cancer
Institute (1998), tumours with instability at 30% or more of the
tested microsatellite loci were classified as highly microsatellite
unstable (MSI-H), those with instability at less than 30% of tested
markers as low microsatellite unstable (MSI-L), and tumours with
stability in all tested loci as microsatellite stable (MSS) (Boland
et al, 1998). Low microsatellite unstable and MSS tumours were
Table 1 Clinical criteria indicative for HNPCC
Clinical criteria for HNPCC
Amsterdam
At least three family members with histologically verified colorectal cancer
One case a first degree relative
At least two successive generations affected
At least one case diagnosed before the age of 50
Exclusion of FAP
Bethesda 2
Synchronous or metachronous colorectal carcinomas or HNPCC-related cancers (endometrium, ovary, stomach, bile duct, small bowel, urothelium)
Bethesda 3
Colorectal cancer and one first degree relative with colorectal cancer or HNPCC-related cancer (diagnosis before the age of 45) and/or colorectal adenoma (diagnosis
before the age of 40)
Bethesda 4
Colorectal or endometrial cancer, diagnosed before the age of 45
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2003) and are referred to as ‘MSS’ in this paper.
Pathohistological evaluation
In all, 2mm tissue sections were deparaffinised and stained with
hematoxylin and eosin (HE) following standard protocols.
Antitumoural lymphoid reaction and presence of a CLR were
evaluated in HE-stained sections from 1 to 3 paraffin blocks of the
same tumour (Figure 1). The recommendations of the German
HNPCC Consortium were applied (Ruschoff et al, 2004). The
presence or absence of CLR was scored as 1 or 0, repsectively. For a
positive score, at least three nodular lymphocyte aggregations had
to be detectable in the sample (Figure 1), the presence of germinal
centres was not mandatory. In two cases, CLR presence could not
be evaluated, because the tumour invasion front was not detectable
in the paraffin-embedded material.
Histological evaluation was carried out by three observers (AB,
HB, MK) not aware of MSI status or tumour stage. In patients with
synchronous tumours, the most advanced tumour was used for the
analysis. In eight of 20 cases with synchronous carcinomas, 2–6
different tumours were evaluated. Without exception, scoring was
the same for all synchronous tumours (data not shown).
Tumour staging
For staging, the UICC/AJCC TNM system was applied (AJCC,
1997).
Statistical analysis
The primary end point for the analysis was survival time from the
date of first tumour diagnosis. The median follow-up for survival
was calculated according to the method of Korn (1986). Pairwise
comparisons of the distributions of categorical data were
performed using Fisher’s exact test. The 95% confidence intervals
(CI95) for binomial probabilities were computed using the score-
test-based approach of Wilson (Agresti and Coull, 1998). The
pairwise comparison of the distribution of age at diagnosis was
performed using the Wilcoxon rank sum test and for the pairwise
comparison of survival time distributions the log-rank test was
applied. Estimation of survival time distributions was performed
by the method of Kaplan and Meier. A Cox proportional hazards
regression was used to identify independent prognostic factors for
survival. The model included microsatellite status together with
UICC stage, CLR, and age at diagnosis and 5-FU chemotherapy as
possible prognostic factors. Ordinal logistic regression was used to
model the effect of microsatellite status together with CLR and age
at diagnosis on UICC stage. UICC stages I and II were combined
for the regression analyses. Assuming ‘missing at random’, missing
value imputation was performed for two missing values of CLR. An
effect was judged as statistically significant at a P-value not larger
than 5%. To provide quantitative information on the relevance of
the results 95CI of odds ratios (OR) and hazard ratios (HR) were
computed. The statistical analyses were performed by the
statistical software package R, version 1.8.1 (R Development Core
Team, 2003) together with the Design software library (Harrell,
2001).
RESULTS
Microsatellite status and associated characteristics
Microsatellite analysis of the tumour samples from 120 Bethesda-
positive patients examined in this study revealed an MSI-H
phenotype in 47 (39.2%) cases, 73 (60.8%) were non-MSI-H (64
MSS, nine MSI-L). Patients in the MSI-H group (median 39 years)
were ‘younger’ than patients in the MSS collective (median 43
years, exact Wilcoxon’s rank sum test: P¼0.02); the median age at
time of first diagnosis was 42 years (Table 2).
Clinical criteria were distributed unequally among MSI-H and
MSS group (Fisher’s exact test: P¼0.01). The most obvious
discrepancy was observed for Amsterdam-positive cases, which
were much more frequent in the MSI-H (14/47, 30.1%) than in the
MSS group (7/73, 9.6%, Fisher’s exact test: P¼0.006, Table 2).
The trend towards a more advanced tumour stage observed in
the MSS CRC group (Fisher’s exact test: Po0.001, Table 2) is
reflected by the higher frequency of patients treated with 5-FU
chemotherapy (Fisher’s exact test: P¼0.04, Table 2).
For comparison of tumour localisation with microsatellite
status, only patients with single carcinomas (n¼100) were
evaluated. As expected, right-sided location correlated closely
with the MSI-H phenotype. Among 30 carcinomas in the proximal
colon, 20 were MSI-H (66.7%), in the group of tumors with distal
location, only 18 of 70 tumours (25.7%) displayed the MSI-H
phenotype (Fisher’s exact test: Po0.001, Table 2).
Figure 1 Histological evaluation of Crohn’s like reaction. HE-stained
sections of MSI-H tumours with marked lymphocyte infiltration. (A)
Exemplary illustration of Crohn’s like lesions (black arrows) with apparent
germinal centres surrounding the invasion front of the tumour ( 100
magnification). (B) Peritumoural lymphocytes surrounding the penetration
border of the primary tumour like a cap ( 50). Note the pronounced
Crohn’s like lymphoid reaction. Germinal centres that were not mandatory
for the diagnosis of CLR are clearly detectable in both tumour sections.
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CLRs were found in only 14 from 71 MSS tumours (19.7%). Thus,
CLR frequency was significantly elevated in MSI-H colorectal
cancers (Fisher’s exact test: Po0.001, Table 2).
Patients’ overall survival
The median follow-up was 33 months from the date of first
diagnosis, 29 patients died within the follow-up period. The
survival distribution of MSI-H patients differed significantly from
that of MSS patients (log-rank test: Po0.001, Table 2). Kaplan–
Meier estimates of the survival time distributions are presented in
Figure 2. The estimated 5-year survival rate of MSI-H patients was
88% (CI95: 77–100%) compared to 56% (CI95: 42–75%) in the
MSS group (Figure 2A; log-rank test: Po0.001). An improved
overall survival was also observed in patients with CLRþCRC
(Figure 2B, P¼0.04). No significant differences were observed in
groups with or without 5-FU chemotherapy (not shown).
Additionally, we tested the prognostic value of microsatellite
status together with UICC stage, presence of CLR, and age at
diagnosis and application of 5-FU chemotherapy by using a
proportional hazards regression model. Here, UICC stage and age
at diagnosis were the only statistically significant prognostic
factors for overall survival (Table 3).
The MSI-H phenotype was rarely detected in stage UICC IV:
only six out of 43 (13.9%) tumours with distant metastases
(UICC IV) were MSI-H, compared to 41 out of 77 (53.2%) in the
collective with UICC I-III (Fisher’s exact test: Po0.001, Table 2).
For presence of CLR, the observed tendency was similar. From
42 UICC IV cases that could be scored for lymphocyte infiltration
at primary tumour site, only seven (16.7%) primary tumours
had a marked peritumoural lymphocyte infiltration with CLR,
whereas in the collective with UICC grade I–III the relation of
CLR-positive tumours was 35 out of 76 (46.1%, Fisher’s exact test:
P¼0.001).
Comparison of overall survival after stratification by micro-
satellite status and presence of CLR is shown in Figure 2C and D
for tumours infiltrating the lamina muscularis propria (all other T
stages did not reveal significant results). A lower risk was observed
for patients with MSI-H T3 carcinomas (log-rank test: P¼0.003,
Figure 2C) but this result could not be confirmed by multiple
proportional hazards regression analysis (Table 3).
Table 2 Characteristics of the 120 included colorectal cancer patients
All patients (n¼120) Patients with MSI-H tumours (n¼47) Patients with MSS tumours (n¼73) P-value
Age (year, median) 42 39 43 0.02
Clinical criteria
Amsterdam 21 (17.5) 14 (30.1) 7 (9.6) 0.01
Bethesda 2 23 (19.2) 10 (21.3) 13 (17.8)
Bethesda 3 3 (2.5) 0 (0.0) 3 (4.1)
Bethesda 4 73 (60.8) 23 (48.9) 50 (68.5)
Treatment
5-FU 51 (42.5) 14 (29.8) 37 (50.7)
no 5-FU 69 (57.5) 33 (70.2) 36 (49.3) 0.04
Localisation
Proximal colon 30 (25.0) 20 (42.6) 10 (13.7) o0.001
a
Distal 70 (58.3) 18 (38.3) 52 (71.2)
Multiple 20 (16.7) 9 (19.1) 11 (15.1)
Stage of disease (UICC)
I 10 (8.3) 2 (4.3) 8 (11.0) o0.001
II 36 (30.0) 23 (48.9) 13 (17.8)
III 31 (25.8) 16 (34.0) 15 (20.5)
IV 43 (35.8) 6 (12.8) 37 (50.7)
Primary tumour
T1 8 (6.7) 1 (2.1) 7 (9.6) 0.08
T2 13 (10.8) 2 (4.3) 11 (15.1)
T3 76 (63.3) 35 (74.5) 41 (56.2)
T4 23 (19.2) 9 (19.1) 14 (19.2)
Lymph node status
N0 56 (46.7) 26 (55.3) 29 (39.7) 0.25
N1 21 (17.5) 8 (17.0) 15 (20.5)
N2 43 (35.8) 13 (27.7) 29 (39.7)
Distant metastases
M0 77 (64.2) 41 (87.2) 36 (49.3) o0.001
M1 43 (35.8) 6 (12.8) 37 (50.7)
Crohn’s like reaction
Absent (0) 76 (64.4) 20 (42.6) 56 (78.9) o0.001
Present (1) 42 (35.6) 27 (57.4) 15 (21.1)
Survival (months, median) Infinity
b Infinity
c 72 o0.001
aComparison of proximal vs distal tumours, excluding multiple tumours.
bLast patient died at 84 months (est. survival probability¼0.53).
cLast patient died at 84 months (est.
survival probability¼0.78). Numbers in brackets indicate percentage values.
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sMetastasis frequency in correlation to microsatellite status
and CLR
These results raised the question whether the longer overall
survival of patients with MSI-H tumours was linked to the
occurrence of organ metastases. To address this question in more
detail, we stratified the tumours by depth of infiltration and
compared the occurrence of metastases in the MSI-H vs the MSS
group. From 76 T3 carcinomas, 35 (46.1%, CI95: 0.35–0.57) were
MSI-H, hence the MSI-H frequency was comparable to the MSI-H
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Figure 2 Kaplan–Meier estimates of overall survival. (A and B) Patients of all tumour stages stratified by microsatellite status (A) and presence of Crohn’s
like reaction (CLR, B). (C and D) Overall survival of patients with T3 stage colon cancer depending on microsatellite status (C) and CLR (D). P-values
shown were calculated using the log-rank test for survival differences.
Table 3 Cox’s proportional hazards regression for survival
Factor Effect Hazard ratio (95% confidence limits) P-value
All data
Age at diagnosis (year) 10 years difference 1.67 (1.28–2.17) o0.001
MSA MSI-H vs MSS 0.45 (0.15–1.36) 0.16
UICC 0.002
III vs I/II 9.22 (1.02–83.12)
IV vs I/II 28.77 (3.65–226.66)
CLR Present vs absent 0.75 (0.27–2.12) 0.59
5-FU chemotherapy Yes vs no 0.59 (0.26–1.34) 0.21
T 3 carcinomas
Age at diagnos is (year) 10 years difference 1.91 (1.29–2.84) 0.001
MSA MSI-H vs MSS 0.44 (0.09–2.09) 0.30
UICC 0.009
III vs II 6.39 (0.65–62.71)
IV vs II 23.13 (2.62–204.16)
CLR Present vs absent 0.49 (0.11–2.22) 0.35
5-FU chemotherapy Yes vs no 1.55 (0.53–4.53) 0.42
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sfrequency observed overall in all included patients (39.2%, CI95:
0.31–0.48).
T3 cancers with MSI-H had organ metastases defining UICC IV
stage in 4/35 cases (11.4%), while those with MSS phenotype in
almost half of the cases (20 out of 41, 48.8%, Table 4). The
increased frequency of metastases in MSS T3 cases was highly
significant (Fisher’s exact test: Po0.001, Table 4).
To clarify whether this observation was related to morphological
features of an antitumoural immune response, T3 tumours were
grouped according to the presence of a CLR. The comparison of M
stage in T3 carcinomas with or without CLR revealed a trend
towards a lower frequency of metastases in cases with CLR (six out
of 29 M1 in CLRþ T3 tumours vs 17 out of 45 M1 in CLR ,
P¼0.13, Table 4).
In summary, we observed a markedly reduced frequency of
organ metastases in T3 colorectal cancers that exhibited either the
MSI-H phenotype, a CLR or both.
In regard to lymph node metastases, differences were neither
significant after stratification for microsatellite status nor for CLR
presence (P¼0.28 and 0.51, respectively, Table 4).
To test microsatellite status and CLR as predictors of UICC
tumour stage, a logistic regression model was applied (Table 5).
For CLR, the statistically significant correlation was limited to the
regression analysis that included tumours of all T stages (OR 0.44,
P¼0.04). In contrast, MSI-H was significantly associated with a
lower UICC stage when looking at all tumours (OR 0.33, P¼0.006)
and also in the T3 subgroup (OR 0.24, P¼0.006). These data show
that the improved overall survival of patients with MSI-H CRC
included in this study is closely linked to lower rates of distant
metastases, even after stratification for local depth of invasion of
the primary tumour.
DISCUSSION
In this study, we analysed the impact of MSI and Crohn’s like
lymphoid reaction on the course of disease in 120 colorectal cancer
patients fulfilling clinical criteria suggesting HNPCC. Our inclu-
sion criteria resulted in a cohort of patients with an age at
diagnosis younger than in a random population of patients with
colon cancer. This strategy significantly increases the number of
MSI-H cases. Focusing on Bethesda-positive patients results in a
stratification that may provide a better comparability of MSI-H
and MSS cases, as clinical differences between the two collectives
are reduced. It is important to note, that none of the included
patients were from families in which HNPCC had previously been
confirmed. Therefore, a statistical bias towards an earlier detection
of MSI cases due to an intensified screening of persons at risk can
be excluded. Furthermore, MSI status had no influence on
operative or perioperative treatment as this was generally not
known before the time of operation. All patients received a
standardised oncologic colorectal resection in the No-Touch-
Isolation technique originally described by Turnbull (1975) unless
when in a palliative noncurative situation.
When comparing MSS and MSI-H cases, significant differences
were found for distribution of clinical criteria, tumour localisation,
UICC stage of disease, M stage, vital status of patients and presence
of CLR.
Not surprisingly, the predictive value for microsatellite unstable
tumours was highest for Amsterdam criteria. In two-thirds of
Amsterdam positive cases tumours were diagnosed as MSI-H. For
our further analyses, no discrimination was made between
sporadic cases and cases with a positive family history as the
microsatellite status of the tumour itself was believed to be crucial
for its histological appearance and biological behaviour. This
approach is supported by a large study comparing HNPCC-
associated and sporadic MSI-H CRCs where no significant
histopathological differences were found, except a marginally
higher frequency of mucinous tumours in cases with positive
family history (Shia et al, 2003).
To analyse the antitumoural immune reaction of the host, we
focused on the presence of a CLR and not on the density of
intratumoural lymphocytes. This strategy was chosen to directly
address the stromal inflammatory reaction. Furthermore, the
interobserver reproducibility has been reported to be much better
for the assessment of CLR than for counting of tumour-infiltrating
lymphocytes (Alexander et al, 2001). Moreover, preliminary data
with a limited number of tumour samples indicated a good
Table 4 Frequency of metastases in patients with T3 colorectal cancers stratified by microsatellite status and presence of Crohn’s like reaction
All T3 tumours (n¼76) T3 tumours MSI-H T3 tumours MSS P-value T3 tumours CLR positive T3 tumours CLR negative P-value
Lymph node status
N0 36 (47.4) 20 (57.1) 16 (39.0) 0.28 16 (57.1) 20 (43.4) 0.51
N1 14 (18.9) 5 (14.3) 9 (22.0) 4 (14.3) 9 (19.6)
N2 26 (35.1) 10 (28.6) 16 (39.0) 8 (28.6) 17 (37.0)
Distant metastases
M0 52 (68.4) 31 (88.6) 21 (51.2) o0.001 23 (79.3) 28 (62.2) 0.13
M1 24 (31.6) 4 (11.4) 20 (48.8) 6 (20.7) 17 (37.8)
Table 5 Ordinal logistic regression for UICC
Factor Effect Odds ratio (95% confidence limits) P-value
All data
Age at diagnosis (year) 10 years difference 0.88 (0.67–1.16) 0.36
MSA MSI-H vs MSS 0.33 (0.15–0.72) 0.006
CLR Present vs absent 0.44 (0.19–0.98) 0.04
T 3 carcinomas
Age at diagnosis (year) 10 years difference 0.70 (0.50–0.98) 0.04
MSA MSI-H vs MSS 0.24 (0.08–0.66) 0.006
CLR Present vs absent 0.93 (0.33–2.60) 0.88
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scorrelation of CLR with a high density of tumor-infiltrating
cytotoxic (CD8þ) lymphocytes, supporting the hypothesis that
CLR positivity is indeed associated with a cytotoxic antitumoural
immune response.
As in previous reports, we could show that the presence
of a CLR was closely associated with a microsatellite unstable
phenotype of colorectal cancer (Gafa et al, 2000). The strong
antitumoural lymphoid reaction, which frequently occurs in MSI-
H colorectal cancers, is commonly attributed to tumour-specific
neopeptides generated during MSI-H carcinogenesis. Functional in
vitro assays proved the immunogenicity of certain MSI-associated
frameshift peptides (Linnebacher et al, 2001; Saeterdal et al, 2001;
Ripberger et al, 2003). Both features, MSI-H status and CLR, have
been reported to be associated with longer survival times in
previous studies. When analysing the overall survival in our total
collective stratified for microsatellite status or Crohn’s like
lymphoid reaction, the prognosis of patients with tumours
displaying MSI-H and/or CLR was significantly better. After
having found the differences in survival and the low frequency
of MSI-H in UICC IV tumours, we hypothesised that the above
prognostic advantage of MSI-H tumours was, at least in part, due
to a reduced metastatic potential of these. Therefore, we stratified
the CRCs for penetration depth of primary tumour and compared
the frequency of distant metastases, which proved to be
significantly lower in the MSI-H group. Similar observations had
previously been reported for CRC patients with family history of
HNPCC (Watson et al, 1998), however tumours were not tested for
MSI, and sporadic CRC cases were chosen as a control group.
The observation that microsatellite status was an independent
predictor of distant metastases suggests either a reduced tendency
of MSI-H tumour cells to form metastases, a better antimetastatic
response of the host in MSI-H cases, or both. To further examine
the role of inflammatory reaction in this context, T3 cancers were
grouped for CLR status and frequencies of metastases were
compared. Here, a clear trend towards fewer metastases in CLR
positive cases was observed. One might speculate that the lack of
statistical significance merely reflects variability in CLR scoring
which is more pronounced than in MSI testing. Moreover, CLR
assessment only refers to morphological aspects, yet not to
functional features of tumour infiltrating lymphocytes. An effective
antitumoural immune reaction of the host may not necessarily be
linked to density of tumour-infiltrating lymphocytes or presence of
CLR. The fact, that MSI-H status is much more closely linked to
fewer distant metastases than lymphoid reaction, raises the
question whether there are additional features of microsatellite
unstable cells that contribute to a lower metastatic potential, e.g.
mutations in a number of metastasis-promoting genes. However,
the presence of an antimetastatic immune protection in MSI-H
CRC patients may explain recent findings that adjuvant 5-FU
chemotherapy has no beneficial or even adverse effects in this
collective (Ribic et al, 2003; Carethers et al, 2004). Further
functional studies are needed to clarify the molecular mechanisms
underlying these phenomena. This hypothesis cannot be addressed
in our study, because 5-FU chemotherapy was not administered in
the framework of a controlled trial. Larger prospective studies are
required to clarify the clinical consequences of 5-FU therapy in
MSS or MSI-H CRC patients and the mechanisms underlying these
phenomena.
In summary, this study shows for the first time that MSI-H and
CLRþ CRCs from Bethesda-positive patients are associated with
fewer distant metastases, even in the case of deep local invasion of
the primary tumour. Our data suggest a protective role of
functionally active lymphocytes directed against MSI-H CRCs,
which may prevent tumour cell dissemination and metastasis
formation in distant organs. This observation could be explained
by frameshift mutations occurring within the coding region of
different genes, which lead to tumour-specific neopeptides in MSI-
H tumours. This makes vaccination against these neopeptides a
promising approach for novel adjuvant treatment strategies in
patients with MSI-H tumours. In MMR gene mutation carriers, a
preventive vaccine with a set of predictable neopeptides frequently
affected during MSI tumorigenesis could inhibit or at least delay
the onset of MMR-deficient tumours. In conclusion, due to its
prognostic and potentially therapeutic implications MSI screening
should be considered as a routine diagnostic service in all
colorectal cancer cases in the future.
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